Company profile: Microbix
1.1 - Company Overview
Company description
- Provider of biological products and technologies for the diagnostics market, offering external quality controls (QAPs) for respiratory viral, STI, HPV, and gastrointestinal panels; antigens for immunoassays covering childhood diseases, dengue, STIs, ToRCH, and respiratory infections; DxTM viral transport medium for specimen collection, transport, and storage; and custom vial filling services.
Products and services
- Antigens: Immunoassay-grade biological materials utilized in immunoassays, including antigens for childhood diseases, dengue, STIs, ToRCH, and respiratory infections
- DxTM™ Viral Transport Medium: Laboratory-grade medium used for the collection, transport, and storage of viral specimens for diagnostic testing
- External Quality Controls (QAPs™): Diagnostic-grade quality control materials for various diagnostic tests, including respiratory viral, STI, HPV, and gastrointestinal panels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Microbix
Tagarno
HQ: Denmark
Website
- Description: Provider of digital microscopes with 60 FPS, auto focus, and ergonomic design for specialists in materials science, agriculture, food, electronics, and forensics. Portfolio includes TREND for quality control with apps and accessories, FRONT for high-power inspections, MOVE and ZAP flexarm models, and ZIP for simple magnification and high-quality image capture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tagarno company profile →
PacBio
HQ: United States
Website
- Description: Provider of sequencing systems and technologies for genomic, epigenomic, and transcriptomic analysis, including Revio long-read sequencing, Onso short-read with Sequencing by Binding (SBB) for high accuracy, rare variant detection and difficult-region analysis, Sequel IIe for HiFi reads in whole-genome and RNA sequencing, HiFi sequencing, and Kinnex kits for high-throughput RNA workflows (full-length, single-cell, 16S rRNA).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PacBio company profile →
bit.bio
HQ: United Kingdom
Website
- Description: Provider of proprietary cell programming technology and human iPSC-derived cell products for research and drug discovery. Bit.bio develops opti-ox to convert iPSCs into mature, functional human cells and offers ioCells for consistent, scalable supply. The company applies computational principles to biology to code cells for health, including collaboration with The Michael J. Fox Foundation on Parkinson’s research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full bit.bio company profile →
Nanopoint Imaging
HQ: United States
Website
- Description: Provider of unique cellular experimentation systems for the life sciences market, offering a microfluidics platform that enables multi-day experimentation in a controlled environment and integrates with live cell imaging for greater precision.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanopoint Imaging company profile →
Definigen
HQ: United Kingdom
Website
- Description: Provider of in-vitro liver and metabolic disease models using iPSC technology to generate pre-clinical human data, offering Opti-HEPs for drug efficacy and predictive toxicology screening, phenotypic screening with bioassays, and custom disease model development via CRISPR. Includes models for Alpha-1 Antitrypsin Deficiency, Wilson's Disease (ATP7B), and Glycogen Storage Disease Type 1 Alpha.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Definigen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Microbix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Microbix
2.2 - Growth funds investing in similar companies to Microbix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Microbix
4.2 - Public trading comparable groups for Microbix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →